IMV Inc. (IMVIF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.30: the stock has moved about 70% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerIMV Inc. (IMVIF) trades at $0.002. IMV Inc. is a clinical-stage biopharmaceutical company specializing in immuno-oncology therapies. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for IMVIF: IMVIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
IMV Inc. (IMVIF) Healthcare & Pipeline Overview
IMV Inc. (IMVIF) is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer and infectious diseases, leveraging its proprietary DPX platform to create targeted treatments for solid tumors and blood cancers.
What Is the Investment Thesis for IMVIF?
The company is advancing its lead candidate, maveropepimut-S, through critical Phase II trials, which could unlock significant market opportunities in the oncology space, particularly if successful in treating diffuse large B-cell lymphoma and ovarian cancer. Additionally, IMV's development of immunotherapies for infectious diseases like COVID-19 and RSV adds diversification to its portfolio. However, potential risks include the inherent uncertainties of clinical trial outcomes and the challenges of securing funding in a competitive landscape. The company's ability to navigate these challenges while advancing its clinical programs will be key to unlocking shareholder value.
Based on FMP financials and quantitative analysis
IMVIF Key Highlights
Market Cap: $0.00B, indicating a focus on clinical development with no current revenue.
- Beta: 0.30, suggesting lower volatility compared to the market.
- Employee count: 63, reflecting a lean operational structure.
- No dividend yield, emphasizing reinvestment in clinical trials and research.
- Focus on immuno-oncology, a rapidly growing sector within biotechnology.
Who Are IMVIF's Competitors?
IMVIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | $61.28 | -0.32% | $125B | 92 5-pillar |
| NVS Novartis AG | $153.60 | +1.64% | $292B | 86 5-pillar |
| JAZZ Jazz Pharmaceuticals plc | $205.70 | -3.88% | $13.4B | 40 5-pillar |
| NVO Novo Nordisk A/S | $39.13 | +0.20% | $173B | 91 5-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $517.49 | -1.23% | $131B | 97 5-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $807.67 | +0.33% | $83.2B | 95 5-pillar |
| ARGX argenx SE | $869.33 | -0.50% | $54.7B | 97 5-pillar |
| ALNY Alnylam Pharmaceuticals, Inc. | $231.49 | +3.33% | $31.0B | 91 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IMVIF's Key Strengths?
Innovative DPX platform enabling targeted immunotherapy development.
- Strong pipeline with multiple candidates in clinical trials.
- Experienced management team with expertise in biotechnology.
- Established presence in the immuno-oncology sector.
What Are IMVIF's Weaknesses?
Currently no revenue, relying on funding for operations.
- Clinical-stage status involves significant risks and uncertainties.
- Limited market presence compared to larger competitors.
- Potential challenges in securing additional funding.
What Are the Key Risks for IMVIF?
Financial-distress signal — its Altman Z-Score of -11.76 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 7 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial outcomes remain uncertain and can impact stock performance.
- Regulatory challenges could delay product development timelines.
- Competition from established pharmaceutical companies in immuno-oncology.
- Market volatility affecting investor sentiment and funding availability.
What Are IMVIF's Competitive Advantages?
- Proprietary DPX immune-modulating platform that enhances immune responses.
- Focused expertise in immuno-oncology, differentiating it from competitors.
- Innovative drug delivery technology that targets specific cancer cells.
- Strong pipeline of clinical candidates addressing unmet medical needs.
- Established reputation in the biotechnology community since 2000.
What Does IMVIF Do?
Founded in 2000, IMV Inc., originally known as Immunovaccine Inc., is a biopharmaceutical firm headquartered in Dartmouth, Canada. The company is dedicated to advancing immuno-oncology therapies through its proprietary DPX immune-modulating platform, which enables the development of a range of treatments targeting both solid tumors and hematological malignancies. IMV's flagship product, maveropepimut-S, is an immunotherapy designed to target cells expressing survivin, currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and various solid tumors, including those of the bladder and liver. Additionally, the company is investigating maveropepimut-S in Phase I trials for breast cancer. IMV's pipeline also includes DPX-SurMAGE, currently in Phase I evaluation for bladder cancer, as well as DPX-COVID-19 and DPX-RSV, which are aimed at addressing infectious diseases. The company has made significant strides since its inception, focusing on developing innovative therapies that leverage its unique drug delivery technology, which is designed to enhance immune responses against cancer cells. With a workforce of 63 employees, IMV Inc. is positioned to capitalize on the growing demand for advanced immunotherapies in the healthcare sector.
What Products and Services Does IMVIF Offer?
- Develop immunotherapies targeting cancer and infectious diseases.
- Utilize the proprietary DPX immune-modulating platform for drug delivery.
- Conduct clinical trials to evaluate the safety and efficacy of its therapies.
- Focus on solid tumors and blood cancers in its treatment pipeline.
- Engage in research collaborations to enhance therapeutic development.
- Seek regulatory approvals for its clinical-stage products.
How Does IMVIF Make Money?
- Generate revenue through the development and commercialization of innovative therapies.
- Engage in partnerships and collaborations with larger pharmaceutical companies.
- Leverage funding from grants and investors to support clinical trials and research.
- Potential future revenue from licensing agreements for its proprietary technologies.
- Focus on advancing clinical candidates to market for revenue generation.
What Industry Does IMVIF Operate In?
The biotechnology industry, particularly the immuno-oncology sector, is experiencing significant growth, driven by advancements in cancer therapies and increasing demand for personalized medicine. IMV Inc. operates in a competitive landscape that includes established players and emerging biotech firms, positioning itself with its proprietary DPX platform, which differentiates its product offerings through targeted immune modulation. As clinical results emerge, companies like IMV that focus on innovative therapies are likely to capture market share and attract investor interest.
Who Are IMVIF's Key Customers?
- Healthcare providers and hospitals seeking advanced cancer treatments.
- Patients diagnosed with solid tumors and blood cancers.
- Pharmaceutical companies interested in collaboration and licensing.
- Research institutions conducting studies in immuno-oncology.
- Investors and stakeholders in the biotechnology sector.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Earnings Track Record
IMV Inc. has missed Wall Street's EPS estimate in 4 of its last 7 reported quarters — a mixed record worth weighing. Reported results have landed about 2.6% below estimates on average.
Financial Health
IMV Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -11.76 places it in the distress zone, a signal of elevated financial risk.
Company Profile
IMV Inc. operates in the Healthcare sector. It is headquartered in Dartmouth, CA. The company is led by CEO Andrew Hall. IMVIF has traded publicly since 2013.
Forward Outlook
Wall Street analysts project IMV Inc. revenue of about $21.4M for fiscal 2026, with EPS near $-2.64.
IMVIF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
IMVIF Latest News
No recent news available for IMVIF.
IMVIF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for IMVIF.
Price Targets
Wall Street price target analysis for IMVIF.
IMVIF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for IMVIF; grades run from A+ (80-100) to F (below 30).
Leadership: Andrew Hall
CEO
Andrew Hall has extensive experience in the biopharmaceutical industry, having held various leadership roles in both public and private companies. He has a strong background in drug development and commercialization, with a focus on oncology and immunotherapy. Hall holds an MBA and has been instrumental in guiding IMV Inc. through its clinical development phases.
Track Record: Under Andrew Hall's leadership, IMV Inc. has advanced its clinical pipeline significantly, particularly with the progress of maveropepimut-S through multiple phases of clinical trials. His strategic vision has positioned the company to explore new therapeutic areas and expand its market reach.
IMVIF OTC Market Information
OTC Other tier stocks, like IMV Inc., are subject to less stringent reporting requirements compared to those listed on major exchanges like NYSE or NASDAQ. This can lead to lower liquidity and potentially higher volatility, as these companies may not be required to file regular financial reports or maintain the same level of transparency.
- OTC Tier: OTC Other
- Lower liquidity compared to stocks listed on major exchanges.
- Less stringent reporting and transparency requirements.
- Potential for higher volatility due to market dynamics.
- Increased risk of price manipulation in less regulated markets.
- Review recent clinical trial results and their implications.
- Assess the company's financial health and funding status.
- Evaluate the competitive landscape and market positioning.
- Monitor regulatory developments affecting the biotechnology sector.
- Investigate potential partnerships or collaborations.
- Established presence in the biotechnology sector since 2000.
- Ongoing clinical trials with potential for significant market impact.
- Experienced management team with a track record in drug development.
What Investors Ask About IMV Inc. (IMVIF) — Healthcare
What are the main risks for IMVIF?
The primary risks for IMV Inc. include uncertainties surrounding clinical trial outcomes, which could significantly affect the company's future. Regulatory challenges may also pose delays in product development.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial information may be limited due to OTC classification.